Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant (NCT03924401)
Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant (ASCENT)
🩺 Plain-English Summary (8th-Grade Level)
This trial will see if extended abatacept administration (combined with a standard regimen of tacrolimus and mycophenolate mofetil) will prevent acute and chronic graft-versus-host disease (GVHD) in children and adolescents receiving unrelated donor (URD) hematopoietic stem cell transplantation (HSCT), without compromising their engraftment or reconstitution of protective immunity to infection. The study will enroll 30 pediatric patients with serious non-malignant hematologic diseases (NMHD) undergoing URD HSCT. The trial will include patients with 7/8 donors and those with 8/8 (matched) donors. All participants will receive 8 doses of abatacept. Recruitment is expected to last for about 2 years and participants will be followed for up to 3 years.
Who can join: Review the eligibility criteria below.
Location: Children's of Alabama — Birmingham, Alabama
Age range: Not specified to 20 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- Children's of Alabama — Birmingham, Alabama
- Nemours/Alfred I. DuPont Hospital for Children — Wilmington, Delaware
- Childrens Healthcare of Atlanta — Atlanta, Georgia
- Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
- Dana-Farber Cancer Institute — Boston, Massachusetts
- University of Mississippi Medical Center, Children's Center for Cancer and Blood Disorders — Jackson, Mississippi
- Hackensack Meridian Health — Hackensack, New Jersey
- Oishei Children's Hospital — Buffalo, New York
- Columbia University Irving Medical Center — New York, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Graft Versus Host Disease
- Optimizing PTCy Dose and Timing — Bethesda, Maryland
- Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation — Duarte, California
- Evaluating the Effects of Propionate and Butyrate Supplementation on the Intestinal Health of Healthy Volunteers — Duarte, California
- PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis — Detroit, Michigan
- A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant — Basking Ridge, New Jersey
Explore by condition: All Graft Versus Host Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.